Full Press Release Details
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer.
MBX
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
Key Takeaway: MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
Price reaction · baseline $27.94 (2026-03-09 close) · hit after-hours · 1 other MBX headline(s) in the window, move may be shared
day 0 close · peak
+3.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+163%
120-day peak, hindsight
Typical move
5.3%
average across 7 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
MBX 4291
Phase 1 · Obesity